SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NewAmsterdam Pharma Company N.V. (NAMS) has a negative trailing P/E of -19.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 21.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.18%, forward earnings yield 4.62%. PEG 0.17 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (96/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.17); analyst target implies upside (+37%).
- Forward P/E 21.7 — analysts expect a return to profitability with estimated EPS of $1.59 for FY2029.
- PEG Ratio 0.17 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -5.18% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 4.62% as earnings recover.
- Analyst consensus target $47.20 (+37% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
96/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NAMS
Valuation Multiples
P/E (TTM)-19.3
Forward P/E21.7
PEG Ratio0.17
Forward PEG0.17
P/B Ratio5.75
P/S Ratio175.63
EV/EBITDA-14.3
Per Share Data
EPS (TTM)$-1.78
Forward EPS (Est.)$1.59
Book Value / Share$5.97
Revenue / Share$0.20
FCF / Share$-1.29
Yields & Fair Value
Earnings Yield-5.18%
Forward Earnings Yield4.62%
Dividend Yield0.00%
Analyst Target$47.20 (+37%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-26.8 |
0.00 |
1.48 |
0.00 |
- |
| 2021 |
-4.1 |
-0.02 |
3.06 |
0.00 |
- |
| 2022 |
-9.1 |
0.14 |
0.48 |
2.01 |
- |
| 2023 |
-5.2 |
-0.06 |
3.18 |
65.13 |
- |
| 2024 |
-10.0 |
-0.53 |
3.20 |
53.22 |
- |
| 2025 |
-19.7 |
0.62 |
5.87 |
178.34 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-1.15 |
$0.00 |
$-5.75M |
- |
| 2021 |
$-3.34 |
$0.00 |
$-36.71M |
- |
| 2022 |
$-1.11 |
$95.91M |
$-21.14M |
-22% |
| 2023 |
$-2.15 |
$12.76M |
$-176.94M |
-1386.4% |
| 2024 |
$-2.56 |
$45.56M |
$-241.6M |
-530.3% |
| 2025 |
$-1.75 |
$22.5M |
$-203.82M |
-905.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.91 |
$-2.48 – $-1.57 |
$25.62M |
$5.88M – $80.26M |
10 |
| 2027 |
$-1.39 |
$-3.90 – $2.85 |
$159.59M |
$20.02M – $499.58M |
8 |
| 2028 |
$-0.21 |
$-0.81 – $0.00 |
$381.69M |
$87.66M – $1.2B |
7 |
| 2029 |
$1.59 |
$0.00 – $6.00 |
$720.31M |
$165.43M – $2.26B |
6 |
| 2030 |
$3.66 |
$-0.01 – $13.82 |
$1.08B |
$248.91M – $3.39B |
6 |
